Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 440NIH 146INDUSTRY 64NETWORK 41OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 1Head & Neck 1Endocrine 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Leukemia, Myeloid, Acute 30Hematologic Neoplasms 20Leukemia 13Multiple Myeloma 9Myelodysplastic Syndromes 8Lymphoma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 7Recurrence 6Lymphoma, Non-Hodgkin 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, B-Cell 3Leukemia, Myelomonocytic, Chronic 3Hodgkin Disease 3Vitamin D Deficiency 2Neoplasms, Plasma Cell 2Neoplasm, Residual 2Motor Activity 2Invasive Fungal Infections 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Diseases 2Cardiovascular Diseases 2Wilms Tumor 1Stomatitis 1Sprains and Strains 1Shoulder Injuries 1Shoulder Dislocation 1Sepsis 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Burkitt Lymphoma × Other hematologic neoplasm × Clear all
NCT05648019 2023-03-09

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

KK Women's and Children's Hospital

Phase 2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡